UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

In the European population HLA-class II genes are not associated with Helicobacter pylori infection

European journal of gastroenterology & hepatology, 2002-01, Vol.14 (1), p.49-53

2002

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori infection and polymorphisms in the tumor necrosis factor region

Electrophoresis, 1999-01, Vol.20 (8), p.1756-1761

1999

Link zum Volltext

Verfügbarkeit prüfen

The Nonfunctional Allele TCRBV6S1B Is Strongly Associated with Helicobacter pylori Infection

Infection and Immunity, 2000-11, Vol.68 (11), p.6493-6495

2000

Link zum Volltext

Verfügbarkeit prüfen

Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Zeitschrift fur Gastroenterologie, 2024-02, Vol.62 (2), p.261

2024

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study

Gut, 2002-06, Vol.50 (6), p.779-785

2002

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori infection: CagA-specific antibodies are associated with clinical outcome, but not with HLA-class II polymorphisms of the host

International journal of medical microbiology, 2003-02, Vol.292 (7-8), p.537-540

2003

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

Alimentary pharmacology & therapeutics, 2006-07, Vol.24 (2), p.395-403

2006

Link zum Volltext

Verfügbarkeit prüfen

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

Wiener Klinische Wochenschrift, 2010-07, Vol.122 (13-14), p.413-422

2010

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Helicobacter pylori

Baillière's best practice & research. Clinical gastroenterology, 2007-01, Vol.21 (2), p.315-324

2007

Link zum Volltext

Verfügbarkeit prüfen

Sequential Metronidazole-Furazolidone or Clarithromycin-Furazolidone Compared to Clarithromycin-Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double-Blind Randomized Controlled Trial

Helicobacter (Cambridge, Mass.), 2010-12, Vol.15 (6), p.497-504

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

Alimentary pharmacology & therapeutics, 2006-02, Vol.23 (4), p.481-488

2006

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori eradication: role of individual therapy constituents and therapy duration

Fundamental & clinical pharmacology, 2009-02, Vol.23 (1), p.43-52

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Rabeprazole, Amoxicillin, and Gatifloxacin After Treatment Failure of Initial Helicobacter pylori Eradication

Helicobacter (Cambridge, Mass.), 2006-08, Vol.11 (4), p.231-236

2006

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Peptic Ulcer

Digestion, 1998-08, Vol.59 (5), p.446-452

Tytgat, Guido N.J.

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

ThemaHelicobacter Pylori

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)
Japanisch
(5)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

In the European population HLA-class II genes are not associated with Helicobacter pylori infection

Helicobacter pylori infection and polymorphisms in the tumor necrosis factor region

The Nonfunctional Allele TCRBV6S1B Is Strongly Associated with Helicobacter pylori Infection

Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study

Helicobacter pylori infection: CagA-specific antibodies are associated with clinical outcome, but not with HLA-class II polymorphisms of the host

Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

Treatment of Helicobacter pylori

Sequential Metronidazole-Furazolidone or Clarithromycin-Furazolidone Compared to Clarithromycin-Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double-Blind Randomized Controlled Trial

Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

Helicobacter pylori eradication: role of individual therapy constituents and therapy duration

Efficacy and Safety of Rabeprazole, Amoxicillin, and Gatifloxacin After Treatment Failure of Initial Helicobacter pylori Eradication

Treatment of Peptic Ulcer

Aktive Filter

Suchergebnisse filtern